Barriers and facilitators to implementation of a metabolic monitoring protocol in hospital and community settings for second-generation antipsychotic-treated youth

Journal of the Canadian Academy of Child and Adolescent Psychiatry

Volumn 20, Issue 2, 2011, Pages 134-141

  Ronsley, Rebecca ^a,b   Raghuram, Kamini ^a   Davidson, Jana ^c   Panagiotopoulos, Constadina ^c  

^a UNIVERSITY OF TORONTO   (Canada)

^b BC CHILDREN S HOSPITAL   (Canada)

^c UNIVERSITY OF BRITISH COLUMBIA   (Canada)

Author keywords

Adolescents; Atypical antipsychotics; Children; Efficacy; Metabolic monitoring

Indexed keywords

ATYPICAL ANTIPSYCHOTIC AGENT;

ABNORMAL LABORATORY RESULT; ARTICLE; CHILD PSYCHIATRY; COMMUNITY CARE; CONTROLLED STUDY; DRUG MONITORING; DRUG SURVEILLANCE PROGRAM; HEALTH CARE ACCESS; HEALTH CARE PLANNING; HEALTH CARE SURVEY; HUMAN; INTERDISCIPLINARY COMMUNICATION; METABOLISM; NURSE ATTITUDE; ONLINE SYSTEM; PATIENT ATTITUDE; PATIENT COMPLIANCE; PATIENT EDUCATION; PATIENT MONITORING; PEDIATRIC HOSPITAL; PHYSICIAN ATTITUDE; PRIMARY MEDICAL CARE; PROFESSIONAL KNOWLEDGE;

EID: 79955937138     PISSN: 17198429     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (22)

1. American Diabetes Association, American Psychiatric Association, American Association of Clinical Endocrinologists, & North American Association for the Study of Obesity (2004). Consensus development conference on antipsychotic drugs and obesity and diabetes. Diabetes Care, 27(2), 596-601.
2. Barnes, T. R., Paton, C., Cavanagh, M. R., Hancock, E., Taylor, D. M. & UK Prescribing Observatory for Mental Health (2007). A UK audit of screening for the metabolic side effects of antipsychotics in community patients. Schizophrenia Bulletin, 33(6), 1397-1403.
3. Cohen, D. (2004). Atypical antipsychotics and new onset diabetes mellitus. an overview of the literature. Pharmacopsychiatry, 37(1), 1-11.
4. Correll, C. U., Manu, P., Olshanskiy, V., Napolitano, B., Kane, J. M., & Malhotra, A. K. (2009). Cardiometabolic risk of second-generation antipsychotic medications during first-time use in children and adolescents. JAMA: The Journal of the American Medical Association, 302(16), 1765-1773.
5. Haupt, D. W., Rosenblatt, L. C., Kim, E., Baker, R. A., Whitehead, R., & Newcomer, J. W. (2009). Prevalence and predictors of lipid and glucose monitoring in commercially insured patients treated with second-generation antipsychotic agents. The American Journal of Psychiatry, 166(3), 345-353.
6. Henderson, D. C. (2002). Atypical antipsychotic-induced diabetes mellitus: How strong is the evidence? CNS Drugs, 16(2), 77-89.
7. Melkersson, K. I., Hulting, A. L., & Brismar, K. E. (2000). Elevated levels of insulin, leptin, and blood lipids in olanzapine-treated patients with schizophrenia or related psychoses. The Journal of Clinical Psychiatry, 61(10), 742-749.
8. Meyer, J. M., Davis, V. G., Goff, D. C., McEvoy, J. P., Nasrallah, H. A., Davis, S. M., et al. (2008). Change in metabolic syndrome parameters with antipsychotic treatment in the CATIE schizophrenia trial: Prospective data from phase 1. SchizophreniaResearch, 101(1-3),273-286.
9. Meyer, J. M. & Koro, C. E. (2004). The effects of antipsychotic therapy on serum lipids: A comprehensive review. Schizophrenia Research, 70(1), 1-17.
10. Morrato, E. H., Druss, B., Hartung, D. M., Valuck, R. J., Allen, R., Campagna, E., et al. (2010). Metabolic testing rates in 3 state Medicaid programs after FDA warnings and ADA/APA recommendations for second-generation antipsychotic drugs. Archives of General Psychiatry, 67(1), 17-24.
11. Nasrallah, H. A. & Newcomer, J. W. (2004). Atypical antipsychotics and metabolic dysregulation: Evaluating the risk/benefit equation and improving the standard of care. Journal of Clinical Psychopharmacology, 24(5 Suppl 1), S7-14.
12. Newcomer, J. W., Nasrallah, H. A., & Loebel, A. D. (2004). The atypical antipsychotic therapy and metabolic issues national survey: Practice patterns and knowledge of psychiatrists. Journal of Clinical Psychopharmacology, 24(5 Suppl 1), S1-6.
13. Panagiotopoulos, C., Ronsley, R., & Davidson, J. (2009). Increased prevalence of obesity and glucose intolerance in youth treated with second-generation antipsychotic medications. Canadian Journal of Psychiatry, 54(11), 743-749.
14. Panagiotopoulos, C., Ronsley, R., Elbe, D., Davidson, J., & Smith, D. H. (2010). First do no harm: Promoting an evidence-based approach to atypical antipsychotic use in children and adolescents. Journal of the Canadian Academy of Child and Adolescent Psychiatry, 19(2), 124-137.
15. Pharmacare (2009). Policy, outcomes evaluation and research, pharmaceutical services division, ministry of health services. Unpublished manuscript.
16. Preskorn, S. H. (2009). A roadmap to key pharmacologic principles in using antipsychotics: Application in clinical practice. The Journal of Clinical Psychiatry, 70(4), 593-600.
17. Scarlota, L. C., Harvey, J. A., & Aloyo, V. J. (2010). The role of serotonin-2 (5-HT(2)) and dopamine receptors in the behavioral actions of the 5-HT(2A/2C) agonist, DOI, and putative 5-HT (2C) inverse agonist, SR46349B. Psychopharmacology, 213(2-3), 393-401.
18. Shirzadi, A. A. & Ghaemi, S. N. (2006). Side effects of atypical antipsychotics: Extrapyramidal symptoms and the metabolic syndrome. Harvard Review of Psychiatry, 14(3), 152-164.
19. Tandon, R. & Halbreich, U. (2003). The second-generation 'atypical' antipsychotics: Similar improved efficacy but different neuroendocrine side effects. Psychoneuroendocrinology, 28 Suppl 1, 1-7.
20. Waddell C. & Shepherd C. (2002). Prevalence of mental disorders in children and youth. Mental Health Evaluation & Community Consultation Unit Research Update, University of British Columbia, October 2002.
21. Walter, G., DeLaroche, A., Soh, N., Hunt, G., Cleary, M., Malhi, G., et al. (2008). Side effects of second-generation antipsychotics: The experiences, views and monitoring practices of Australian child psychiatrists. Australasian Psychiatry: Bulletin of Royal Australian and New Zealand College of Psychiatrists, 16(4), 253-262.
22. Wu, R. R., Zhao, J. P., Liu, Z. N., Zhai, J. G., Guo, X. F., Guo, W. B., et al. (2006). Effects of typical and atypical antipsychotics on glucose-insulin homeostasis and lipid metabolism in first-episode schizophrenia. Psychopharmacology, 186(4), 572-578.